A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial
A Potthoff, H Wedemeyer, WO Boecher, T Berg, S Zeuzem, J Arnold, U Spengler, K Deterding, MP Manns, C Trautwein · Zeitschrift für Gastroenterologie · 2008 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background and Patients: HBV/HCV coinfection has been associated with more severe liver disease and a higher risk of hepatocellular carcinoma. Interferon alpha alone or in combination with ribavirin (RBV) can achieve sustained HCV clearance and long-term HBV-DNA suppression. The aim of this prospective multicenter pilot trial was to assess the efficacy of PEG-IFN-α2b and RBV in HBV/HCV coinfected patients. Nineteen patients with chronic HBV/HCV coinfection were treated with weight adjusted dosing of PEG-IFN-α2b (1.5µg/kg) and RBV (800–1200mg/day) for 48 weeks. All patients were positive for HBsAg, anti-HCV and H…
